Logo

BCPC

Balchem Corporation

BCPC

Balchem Corporation • NASDAQ
$156.21 ▼ -0.20% (-0.31)
Market Cap $5.06 B
52w High $181.79
52w Low $139.17
Dividend Yield 0.87%
P/E 34.11
Volume 61.34K
Outstanding Shares 32.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $267.558M ▲ $40.874M ▼ $40.289M ▲ 15.058% ▲ $1.25 ▲ $76.812M ▲
Q2-2025 $255.467M ▲ $41.671M ▲ $38.278M ▲ 14.984% ▲ $1.18 ▲ $63.18M ▲
Q1-2025 $250.519M ▲ $37.153M ▼ $37.053M ▲ 14.79% ▲ $1.14 ▲ $61.878M ▲
Q4-2024 $240.004M ▲ $38.893M ▲ $33.583M ▼ 13.993% ▼ $1.03 ▼ $58.199M ▼
Q3-2024 $239.94M $37.369M $33.837M 14.102% $1.04 $58.867M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $65.093M ▼ $1.661B ▼ $363.167M ▼ $1.298B ▲
Q2-2025 $65.427M ▲ $1.678B ▲ $410.334M ▲ $1.268B ▲
Q1-2025 $49.901M ▲ $1.618B ▲ $408.854M ▼ $1.209B ▲
Q4-2024 $49.515M ▼ $1.575B ▼ $425.458M ▲ $1.15B ▼
Q3-2024 $73.694M $1.597B $419.718M $1.177B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $40.289M ▲ $65.572M ▲ $-14.942M ▼ $-50.833M ▼ $-334K ▼ $50.669M ▲
Q2-2025 $38.278M ▲ $47.252M ▲ $-6.621M ▼ $-28.76M ▲ $15.526M ▲ $40.439M ▲
Q1-2025 $37.053M ▲ $36.457M ▼ $-5.912M ▲ $-31.969M ▲ $386K ▲ $30.898M ▼
Q4-2024 $33.583M ▼ $52.317M ▲ $-36.959M ▼ $-35.213M ▼ $-24.179M ▼ $39.592M ▼
Q3-2024 $33.837M $51.302M $-9.181M $-34.392M $9.956M $42.154M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product Sales
Product Sales
 $240.00M ▲$250.00M ▲$260.00M ▲$270.00M ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Balchem’s income statement shows a steady, healthy business. Revenue has climbed over the past five years, with only a mild soft patch in the middle, and profits have grown faster than sales. Margins have gradually improved, meaning the company is getting more out of each dollar of revenue. Earnings per share have risen consistently, helped by both higher profits and disciplined cost control. The profile is one of slow‑to‑moderate, but high‑quality, growth rather than boom‑and‑bust swings. The main risk is that the recent pace of improvement may be hard to maintain if input costs rise or demand softens in its end markets.

Balance Sheet

Balance Sheet The balance sheet looks solid and conservative. Total assets have been broadly stable, while shareholder equity has steadily increased, which strengthens the company’s financial backbone. Debt moved up a few years ago—likely tied to investment or acquisitions—but has since been reduced, easing financial risk. Cash on hand is modest rather than abundant, but not worryingly low given the consistent profitability. Overall, Balchem appears to be managing leverage prudently, with a clear tilt toward a strong equity base and a manageable debt load.

Cash Flow

Cash Flow Cash generation is a key strength. Operating cash flow has been consistently positive and has generally trended upward, which indicates that reported profits are backed by real cash, not accounting noise. After investment in equipment and facilities, free cash flow remains solidly positive year after year. Capital spending is steady but not aggressive, suggesting ongoing maintenance and selective growth projects rather than heavy, risky bets. This cash profile gives Balchem flexibility to fund R&D, small acquisitions, and potential shareholder returns without straining its finances. The main watchpoint is that higher future growth ambitions could require a step‑up in investment.

Competitive Edge

Competitive Edge Balchem operates in specialized corners of the nutrition and health ingredients market, where science and reliability matter more than sheer scale. Its edge comes from proprietary delivery technologies like microencapsulation, strong positions in chelated minerals, and leadership in choline and related nutrients. These are backed by patents, long‑standing brands, and a reputation for quality and efficacy. Close collaboration with customers and the ability to customize ingredient systems deepen relationships and make it harder for rivals to displace them. Competition remains, especially from large global chemical and nutrition companies, but Balchem’s focused expertise, branded ingredients, and technical service give it a defensible niche rather than a commodity profile.

Innovation and R&D

Innovation and R&D Innovation is central to Balchem’s strategy. The company invests in applied science around nutrient delivery, stability, absorption, and taste masking, turning that research into branded platforms like VitaShure, BakeShure, MeatShure, Albion Minerals, and VitaCholine. It supports these with clinical and technical studies, building credibility with formulators and brand owners. Recent moves expand into areas such as joint health, cognitive function, women’s health, and products that complement weight‑management drugs—aligning with long‑term wellness trends. Balchem also looks for synergies across acquired technologies and is incorporating sustainability into product design, particularly in animal nutrition. The key risk is that R&D and concept development cycles can be long, and not every innovation will gain commercial traction, but the pipeline appears diversified and well aligned with demand drivers.

Summary

Balchem presents as a high‑quality, specialized ingredients company with steady growth, improving profitability, and a conservative balance sheet. Its cash flows are dependable and comfortably cover day‑to‑day needs and ongoing investment. The business is differentiated by science‑based technologies, strong niche brands, and close customer partnerships, giving it a defensible position in attractive nutrition and health markets. Future growth is likely to be driven more by innovation, expanding health and wellness applications, and selective acquisitions than by sheer volume expansion. Key things to watch include its ability to keep launching successful new ingredients, maintain pricing power against larger competitors, and balance acquisitions and capital spending with its historically cautious financial posture.

NEWS

October 30, 2025 · 9:17 AM UTC

Balchem Corporation to Present at Baird's 55th Annual Global Industrial Conference on November 12, 2025

Read more

September 18, 2025 · 8:33 AM UTC

Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women's Season Opener

Read more